BI’s Article search uses Boolean search capabilities. If you are not familiar with these principles, here are some quick tips.
To search specifically for more than one word, put the search term in quotation marks. For example, “workers compensation”. This will limit your search to that combination of words.
To search for a combination of terms, use quotations and the & symbol. For example, “hurricane” & “loss”.
(Reuters)—CVS Caremark Corp. raised its full-year forecast on Wednesday after reporting a sharp rise in first-quarter sales as the drugstore operator and pharmacy benefits manager continued to win over former patrons of Walgreen Co. stores.
CVS, which operates the CVS drugstore chain and the CVS Caremark pharmacy benefits management business, said net revenue rose 19.9% to $30.8 billion in the quarter, helped by an 8.4% increase in sales at drugstores open at least a year and more business from Medicare recipients.
Its shares rose 2.2% to $45.71 in morning trading.
Walgreen, the largest U.S. drugstore chain, stopped filling prescriptions for patients of Express Scripts, a pharmacy benefits manager, at the end of 2011 after the companies were unable to agree on the terms of their contract.
Walgreen reported a same-store sales decline in the quarter ended February, and again for the month of March.
CVS, with 7,352 U.S. stores, is among the retailers benefiting as Express Scripts patients go elsewhere to get their prescriptions filled and pick up items like shampoo while they're at a drugstore.
CVS Chief Executive Larry Merlo told Reuters that the boost from his rivals' fallout could be long lasting.
"The longer the impasse lasts, the stickier that customer is going to be," Mr. Merlo said. "They're going to have an opportunity to visit a CVS multiple times and begin to establish a relationship with the CVS pharmacists."
CVS raised its full-year profit forecast by 5 cents per share at both ends of its prior forecast, to between $3.23 and $3.33 per share. Analysts were expecting it to earn $3.27 per share, according to Thomson Reuters I/B/E/S.
In the current quarter, it expects the Walgreen-Express Scripts impasse to lift earnings by 3 to 4 cents per share, and CVS forecast adjusted earnings of 78 to 80 cents per share.
CVS estimated that same-store revenues from prescriptions filled would rise 6.5% to 7.5% this quarter and for same-store sales to be up 5% to 6%.
At the same time, the company is not estimating what the benefit of the rift beyond the current quarter could be, because of the possibility Express Scripts and Walgreen could make up.
CVS earned $776 million, or 59 cents a share, in the first quarter, up from $713 million, or 52 cents a share, a year earlier.
On an adjusted basis, CVS earned 65 cents per share, beating analysts' average forecast by 2 cents.
Drugstore revenue rose 9.9% to $16 billion.
The only things that slowed down the company's pharmacy sales were a weak flu season and new generic drugs, which carry lower prices than brand name drugs.
Pharmacy services revenue rose 32.3% to $18.3 billion.
CVS's purchase of Universal American Corp.'s Medicare prescription plan last year has brought in more patients getting their prescriptions filled. Medicare is the U.S. government's health coverage plan for senior citizens.
Pharmacy benefit managers, or PBMs, such as Express Scripts and CVS Caremark administer drug benefits for employers and health plans and run mail-order pharmacies. CVS can add the ability to pick up prescriptions at its namesake drugstores.
Mr. Merlo said he was "optimistic" at this early stage of the PBM "selling season," the annual campaign that hits to land more corporate accounts.
Its two largest PBM rivals, Express Scripts and Medco, merged last month, but at least one analyst does not expect that deal to hurt CVS Caremark's ability to win new contracts.
"It doesn't pose a threat. In many ways this can be good for CVS because they're the clear alternative," said Judson Clark, an analyst with Edward Jones.
So far, CVS has renewed for one-quarter of the contracts coming up for renewal for 2013, which the company said was par for the course at this time of year.
FRANKLIN LAKES, N.J. (Reuters)—Medco Health Solutions Inc. will lose a major pharmacy benefit contract to CVS Caremark Corp. starting next year, sending Medco shares down almost 11% and CVS up nearly 4% Friday.